Research Article
Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis
Table 6
Multivariate logistic regression testing for variables associated with ExRA.
| Criterion predictor | Method Enter | Method forward stepwise | OR | 95% CI | | OR | 95% CI | |
| Age, years | 1.08 | 1.02–1.13 | 0.002 | 1.05 | 1.01–1.10 | 0.015 | Disease duration, years | 1.13 | 1.04–1.23 | 0.002 | 1.09 | 1.02–1.16 | 0.007 | Smoke exposure | 0.70 | 0.25–2.00 | 0.41 | Not in the model | — | — | DAS-28 | 2.24 | 1.42–3.52 | <0.001 | 1.86 | 1.27–2.73 | 0.002 | Functional Impairment (HAQ-Di) | 5.62 | 1.78–17.75 | 0.003 | 4.46 | 1.51–13.14 | 0.007 | CRP mg/L | 1.02 | 1.00–1.05 | 0.025 | Not in the model | — | — | ESR mm/hr | 0.95 | 0.90–0.99 | 0.02 | Not in the model | — | — | RF IU/mL | 1.27 | 0.45–3.54 | 0.64 | Not in the model | — | — | Anti-CCP IU/mL | 1.00 | 0.99–1.01 | 0.84 | Not in the model | — | — | Anti-MCV IU/mL | 1.00 | 0.99–1.002 | 0.63 | Not in the model | — | — | Anti-TNF agents | 1.63 | 0.36–7.50 | 0.53 | Not in the model | — | — |
|
|
DAS28: disease activity score 28-joints assessed; HAQ-Di: Health Assessment Questionnaire-Disability Index; MTX: methotrexate; Anti-CCP: anti-cyclic citrullinated peptide antibodies, OR: odds ratio, 95% CI, 95% confidential intervals.
|